Skip to main content

Table 1 Patient characteristics at baseline

From: The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

  All, n = 57 HORUS, n = 26 UMC Utrecht, n = 20 LUMC, n = 11 p value
Female, n (%) 41 (72) 22 (85) 12 (60) 7 (64) 0.151
Age in years, mean (SD) 56.6 (11.2) 59.3 (10.8) 56.7 (11.6) 50.1 (9.5) 0.072
Disease duration in years, median (IQR) 11.5 (6.3–16.4) 9.9 (4.1–14.4) 13.4 (8.4–17.6) 13.0 (5.2–15.5) 0.463
Smoking status, number (%)
 No 37 (65) 16 (62) 12 (60) 9 (82) 0.421
 Yes 20 (35) 10 (38) 8 (40) 2 (18)
RF positive, number (%) 51 (90) 23 (89) 19 (95) 9 (82) 0.511
ACPA positive, number (%) 44 (80) 19 (79), n = 24 17 (85) 8 (73) 0.711
Menopausal status, females (%)
 Pre-menopausal 14 (25) 6 (23) 5 (25) 3 (27) 0.301
 Post-menopausal 27 (47) 16 (62) 7 (35) 4 (36)
SJC28, median (IQR) 9 (4–16) 9 (4–15) 12 (8–19), n = 19 4 (1–10), n = 8 0.023
TJC28, median (IQR) 15 (10–23) 16 (11–25) 14 (8–17), n = 19 13 (5–24), n = 8 0.353
VAS-GH, 0–100 mm (worst), median (IQR) 64 (45–73) 69 (40–78) 57 (46–69), n = 19 65 (53–84), n = 8 0.363
ESR, mm/h, median (IQR) 37 (21–51) 32 (12–41), n = 24 52 (21–91), n = 18 32 (29–44), n = 7 0.023
CRP, mg/L, median (IQR) 15 (6–34) 11 (5–25), n = 25 29 (11–50), n = 18 13 (5–56), n = 5 0.023
hsCRP, mg/L, median (IQR) NA 10 (3–26) NA NA NA
DAS28-ESR, median (IQR) 6.3 (5.4–7.1) 6.2 (5.0–7.2), n = 25 6.6 (5.8–7.1), n = 18 6.1 (3.8–7.3), n = 8 0.643
DAS28-hsCRP, median (IQR) NA 5.8 (4.6–6.8) NA NA NA
MBDA score, median (IQR) 54 (44–70) 51 (44–67), n = 25 64 (49–74) 55 (34–71), n = 7 0.153
HAQ, median (IQR) 1.8 (1.4–2.1) 1.9 (1.7–2.1) 1.5 (1.1–1.9), n = 11 1.3 (1.3–1.9), n = 7 0.023
SHS, median (IQR) 44 (24–128) NA 61 (29–142), n = 19 25 (21–94), n = 8 0.343
  1. SD standard deviation, IQR interquartile range, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, SJC28 swollen joint count assessing 28 joints, TJC28 tender joint count assessing 28 joints, VAS-GH patient visual analogue scale for general health, ESR erythrocyte sedimentation rate, mm/h millimetre/hour, CRP C-reactive protein, mg/L milligram/litre, hsCRP high-sensitivity CRP, DAS28 disease activity score assessing 28 joints, MBDA multi-biomarker disease activity, HAQ health assessment questionnaire, SHS Sharp/van der Heijde score, NA not applicable
  2. 1Differences between cohorts were analysed using chi-square test
  3. 2Differences between cohorts were analysed using one-way analysis of variance
  4. 3Differences between cohorts were analysed using Kruskal-Wallis test